Documents

Privosegtor and Licaminlimab advance as lead assets, backed by strong cash runway and strategic focus.

Privosegtor improved visual outcomes and preserved retinal structure in optic neuritis patients.

OCS-01 failed phase III endpoints in DME; focus shifts to Privosegtor and licaminlimab.

All proposals passed, with clinical and financial milestones set for 2026–2027.

OCS-01 and Privosegtor clinical milestones achieved; Q1 net loss narrows, cash runway to 2029.

Late-stage pipeline targets major unmet needs in ophthalmology, with key trial readouts through 2027.

Late-stage pipeline targets DME, dry eye, and neuroprotection, with major data readouts in 2024.

Late-stage pipeline targets DME, dry eye, and neuroprotection, with major milestones in 2024–2027.

Advanced late-stage pipeline, secured $210M in equity, and set up major 2026 clinical milestones.

Privosegtor and OCS-01 advance in pivotal trials, targeting major unmet needs in eye disease.

Lead neuroprotective drug OCS-05 enters phase III, targeting a $6–7B U.S. market with no competition.

Accelerated clinical pipeline and robust cash position support multiple pivotal trials into 2029.

FDA alignment enables pivotal Privosegtor trials in AON and NAION, targeting major unmet needs.

Advancing three late-stage assets in ophthalmology and neuro-ophthalmology with strong clinical data.

OCS-01 leads as a first-line DME therapy, with key phase 3 readouts and regulatory milestones ahead.

Pivotal trials advanced, strong cash runway, and expanded financing amid higher net loss.

Innovative therapies and delivery methods are advancing retinal disease treatment, with major milestones ahead.

Late-stage trials in DME, AON, and dry eye disease set up major catalysts through 2026.

Strong clinical progress and upcoming milestones for three novel ophthalmology assets.

Advancing late-stage assets for DME, optic neuritis, and dry eye with major milestones ahead.

Late-stage pipeline targets DME, neuroprotection, and dry eye with multiple 2025 catalysts.

Oculis completed major trial enrollments and secured $206M cash, enabling pipeline progress.